To learn more about the study below, or other studies, please call us at 1-866-444-1132.
Vulvar High-Grade Squamous Intraepithelial Lesion (HSIL)
Researchers with the National Cancer Institute in Bethesda, Maryland are recruiting women with Vulvar High-Grade Squamous Intraepithelial Lesion (HSIL) for a first-of-its-kind treatment study. This study is being done to determine if a personalized immune treatment can rid the body of the HPV virus that causes HSIL, and thereby curing vulvar HSIL. We hope this treatment will prevent the need for surgery that can be disfiguring and/or cause impairment.
About the study:
- The immune treatment is called T cell therapy.
- Immune cells from your own blood will be genetically modified in the laboratory and then given back to you through an IV infusion.
- After the infusion, you will receive up to two doses of aldesleukin to help the immune cells to survive longer.
- Your recovery in our hospital may take 1-3 days until you are well enough to go home.
- You will have frequent monthly visits to the hospital to follow your progress
There is no cost to you for study-related procedures, tests, or medications. Travel may be reimbursed.
Location: NIH Clinical Center, America’s Research Hospital is located on the Metro red line (Medical Center stop) in Bethesda, Maryland.
For more information:
NIH Clinical Center
Office of Patient Recruitment
1- 866-444-1132
TTY: 1-866-411-1010
https://go.usa.gov/xnbdQ
NIH study 17-C-0116